Subject age subtype ETI CD4 (cells/mm3) VL (log copies/mL) NRTI NNRTI PI ya92 23 CRF01-AE D30 367 5.05 None None M46L       M6 626 4.80 None None M46L       M12 609 4.77 None None M46L       M24 585 3.26 None None M46L ya42 27 B D17 330 7.78 T215S Y188L L90M       M6 300 4.15 T215S Y188L L90M       M12 340 4.14 T215S Y188L L90M       M24 270 3.65 T215S Y188L L90M       M51 106 4.20 T215S Y188L L90M Ya15 30 B D30 196 5.7 None None M46M/L       M6 195 4.67 None None None       M12 188 4.45 None None M46M/L       M24 123 5.57 None None M46M/L Ya34 46 CRF01-AE D22 598 4.53 M41L None None       M6 714 3.91 M41L None None       M12 594 3.89 M41L None None       M24 436 3.95 M41L None None Ya231 24 CRF01-AE D40 665 4.11 None None M46I       M6 493   None None M46I       M12 418 4.11 None None M46I       M24 419   None None M46I Ya18 43 CRF01-AE D30 130 4.21 None None M46L       M6 252 4.08 None None M46L       M12 199 3.88 None None M46L       M24 195 4.94 None None M46L Ya95 24 CRF01-AE D39 805 4.75 None None M46L       M6 924 5.09 None None M46L       M12 717 4.67 None None M46L       M24 638   None None M46L Ya22 25 B D50 612 5.51 None None I50I /L       M6 548 3.47 None None None       M12 405 3.25 None None None       M24 291 4.78 None None None Ya25 45 CRF01-AE D17 518 6.07 None None M46L       M6     None None None       M12     None None None       M24 443 4.98 None None None Ya222 19 CRF01-AE D30 807 3.51 None None M46L       M6 549   None None None       M12 410 2.3 None None None       M24 230   None None None ETI, Estimated time of infection

Table 1: The TDR follow up of 10 acute/early patients (including 7 CRF01-AE subtype and 3 B subtype).

Goto home»